Suppr超能文献

利美尼定对清醒去窦主动脉神经大鼠的交感抑制作用。

Sympathoinhibitory action of rilmenidine in conscious sinoaortically denervated rats.

作者信息

Mayorov D, Chernobelski M, Medvedev O

机构信息

Laboratory of Experimental Pharmacology, National Cardiology Research Center, Moscow, Russia.

出版信息

J Cardiovasc Pharmacol. 1993 Aug;22(2):314-20. doi: 10.1097/00005344-199308000-00022.

Abstract

The responses of mean arterial pressure (MAP), heart rate (HR), and renal sympathetic nerve activity (RSNA) to rilmenidine administration and changes in these responses after idazoxan or yohimbine pretreatment were investigated in conscious sinoaortically denervated rats. Intravenous (i.v.) injection of rilmenidine (300 and 600 micrograms/kg) dose-dependently reduced MAP (16 and 24%, respectively) and RSNA (31 and 56%, respectively), whereas bradycardia was similar at both doses of the drug. Intracisternal (i.c.) pretreatment with idazoxan (5 micrograms/kg), alpha 2-adrenoceptor antagonist with a high affinity to imidazoline receptors (IR) prevented rilmenidine-induced decreases in MAP but not in RSNA and HR. Rilmenidine (300 micrograms/kg i.c.) significantly decreased MAP by 24%, RSNA by 32%, and HR by 13%. Pretreatment with idazoxan (1 microgram/kg i.c.) significantly attenuated the hypotensive and sympathoinhibitory effects of rilmenidine, whereas i.c. pretreatment with equimolar to 10-fold higher doses of yohimbine, an alpha 2-antagonist that binds poorly with IR, did not. Both idazoxan and yohimbine failed to affect the rilmenidine-induced bradycardia, however. We concluded that (a) rilmenidine exhibits more marked hypotensive effect when injected i.c. than when injected i.v., (b) a part of the inhibitory effect of i.v.-injected rilmenidine on RSNA may be exerted through idazoxan-insensitive mechanisms which might be activated by peripheral action of the drug, and (c) the hypotensive action of rilmenidine relates more to the interaction with IR than with alpha 2-adrenoceptors.

摘要

在清醒的经窦主动脉去神经支配的大鼠中,研究了平均动脉压(MAP)、心率(HR)和肾交感神经活动(RSNA)对瑞米吉仑给药的反应以及在给予咪唑克生或育亨宾预处理后这些反应的变化。静脉注射(i.v.)瑞米吉仑(300和600微克/千克)剂量依赖性地降低MAP(分别为16%和24%)和RSNA(分别为31%和56%),而两种剂量的药物引起的心动过缓相似。对咪唑啉受体(IR)具有高亲和力的α2 -肾上腺素能受体拮抗剂咪唑克生(5微克/千克)经脑池内(i.c.)预处理可防止瑞米吉仑引起的MAP降低,但不能防止RSNA和HR降低。瑞米吉仑(300微克/千克,i.c.)可使MAP显著降低24%,RSNA降低32%,HR降低13%。咪唑克生(1微克/千克,i.c.)预处理可显著减弱瑞米吉仑的降压和交感抑制作用,而与IR结合不佳的α2 -拮抗剂育亨宾等摩尔至10倍高剂量的i.c.预处理则不能。然而,咪唑克生和育亨宾均未影响瑞米吉仑引起的心动过缓。我们得出结论:(a)瑞米吉仑经i.c.注射时比经i.v.注射表现出更显著的降压作用;(b)静脉注射的瑞米吉仑对RSNA的部分抑制作用可能通过咪唑克生不敏感的机制发挥,这些机制可能由药物的外周作用激活;(c)瑞米吉仑的降压作用与IR的相互作用比与α2 -肾上腺素能受体的相互作用更相关。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验